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essential. In patients with intestinal symptoms after HCT, upper endoscopy with duo­
denal biopsy and sigmoidoscopy has an acceptable diagnostic yield for intestinal 
involvement
Clinical trial identification: Prospective study
Legal entity responsible for the study: Local ethics committee
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Disclosure: All authors have declared no conflicts of interest.
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Background: Febrile neutropenia remains one of the major concerns of intensive 
chemotherapy and contributes significantly to morbidity, health care expenditure and 
mortality. Colonization of gut by MDR bacteria is regarded as a potential risk factor for 
subsequent infection with the same organism during febrile neutropenia. In this study, 
we aim t<f find the profile of surveillance stool culture and its association with febrile 
neutropenia in patients of acute leukemia undergoing induction chemotherapy. 
Methods: Newly diagnosed patients o f acute leukemia eligible for intensive chemother­
apy were recruited for the study. Baseline stool microscopy and culture sensitivity was 
done to identify colonization with pathogenic bacteria. Blood and other samples were 
collected during febrile neutropenia. Association between surveillance stool culture 
and subsequent infections were studied.
Results: A total of 106 patients were recruited from November 2015 to March 2017.59 
patients were pediatric AL with median age of 10 years and 47 patients were adult AL 
with median age of 33 years. 68.86% of patients had gut colonization with bacteria of 
which 33.01% were MDR while 35.84% were non-MDR. Most erfmmon MDR bacteria 
colonizing gut were E. Coli (62.16%) and Klebsiella Pneumonia (21.82%). A total of 
264 blood cultures were taken from 68 patients who developed 114 episodes FN during 
induction. Blood culture positivity rate was 17.80% with 68.08% of the isolates being 
MDR. Most common MDR isolates were Klebsiella (28.12%) and pseudomonas 
(18.75%). 34.28% of patients colonized with MDR bacteria developed MDR sepsis dur­
ing induction compared to 23.68% non MDR colonizers. Induction mortality was 20% 
in MDR colonizers compared to 10.52% in non-colonizers.
Conclusions: Our study suggests that a significant proportion o f patients are colonized 
with MDR bacteria and there is a high prevalance o f MDR sepsis during induction. 
MDR sepsis and induction mortality were higher in patients colonized with MDR bac­
teria compared to non M DR bacteria.
Legal entity responsible for the study: JIPMER 
Funding: JIPMER
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Background: The risk of anthracydine cardiotoxicity (AC) significantly increases in 
patients with comorbid ischemic heart disease (IHD), which requires monitoring and 
prevention during chemotherapy (СГ) of acute leukemia (AL). In this study we aim to 
evaluate the effectiveness of L-arginine in AC prevention in AL patients with comorbid 
IHD during induction CT.
Methods: A total 66 patients with newly diagnosed AL and comorbid IHD were 
included in the study, ECOG I-Il. The cohort consisted of 34 (51.5%) males and 32 
(48.5%) females, age 54-72 years. The II ID duration was 3-15 years. CT included doxo­
rubicin. We determined thelevd o f troponin I, nitrite anions [NO*]*, performed daily 
ECG-raonitoring: at baseline and in achieving a cumulative dose of anthracyclines 
(CDA) from 100 to 200 mg/m2. Depending on AC prevention patients were divided 
into two groups: I (n =  36) -  AL patients treated with CT; II (n =  30) -  AL patients 
treated with CT and L-arginine.
Results: Prior to CT, according to the daily ECG-monitoring in 47 (71.2%) patients' 
periods of tachycardia were diagnosed, with single supraventricular extrasystoles (SEs) 
and ventricular extrasystoles (VEs) -  in 35 (53%) and 17 (25.7%) pts, respectively. The 
decreased concentration of I NOj] in blood serum in 1.5 times relative to normal values 
(p<0.05) was noticed. Troponin I in all patients of both groups was <0,5 ng/ml. 
Reaching low CDA in group I we recorded: periods of tachycardia in 36 (100%) pts, 
increasing number of single and paired SEs -  in 24 (66.6%), VEs episodes -  in 19 
(52%), clinically significant ST-segment depression -  in 29 (80.5%) and interval QT 
prolongation -  in 14 (38.8%) pts. Troponin 1 was >0.5 ng/ml in 7 (19.4%) pts. 
Simultaneously, deepening of endothelial dysfunction (ED) was noted: [N 02| was in
1.8 times lower vs norm. After 2 CT courses in 20 (66.6%) patients o f group II on tachy­
cardia background the single SEs were recorded and only in 1 (3.3%) patient troponin I 
level was >0.5 ng/ml. The ED leveled: (NOj)' didn’t significantly differ from the norm. 
Conclusions: Thus, L-arginine in AL patients with comorbid IHD during induction 
CT leads to reducing the risk of necrotic injury o f cardiomyocytes and improves endo­
thelial function that prevents early AC.
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Background: Patients with multiple myeloma (MM) often have cardiac comorbidities 
because of several factors, including the history o f cardiac events, myeloma and 
treatment-related factors. Age is an important risk factor, given that the median age at 
the diagnosis of MM in Russia is 64 years. Additionally, the MM-related cardiac risk 
factors include underlying and undiagnosed cardiac amyloidosis, hyperviscosity, high- 
output failure, anemia and renal failure. Therefore, there are poorly understanding of 
real efficiency anti-myeloma treatment for this category of patients. In the presented 
work we have analyzed the efficiency of the most commonly used bortezomib- 
containing regimens in anti-myeloma treatment for patients with MM with concomi­
tant cardiac diseases.
Methods: One hundred and forty-eight (males -  69, females -  79) patients were en­
rolled in this trial during March 2008 -  May 2010. They divided on groups with (1) 
newly diagnosed and (2) relapsed and refractory MM. The median ages for patients of 
all groups was 64.7 years (ranges, 36.3 -  82.7). An obligatory condition was the presence 
in all patients of significant cardiac pathology. Thebortezomib-containing regimens 
VCD (n =  95), VMP (n =  36) or VD (n = 1 5 ) were used as anti-myeloma treatment. 
IMWG (2006) criteria were used for anti-myeloma response assessment. Comparisons 
for categorical variables among different groups were wade with chi-square test.
Overall survival (OS) was measured from the date of treatment initiation until the date 
of death or the date of last follow up. For multivariant analysis, factors associated with 
time to event were introduced into a Cox proportional model.
Results: ECOG performance status of <  2 have 81 (54.7%) patients. The verified diag­
nosis of ischemic heart disease was in 109 (73.6%) patients and symptoms o f chronic 
heart failure was in 86 (58.1%) patients. The overall response rate (ORR) documented 
in 65.7% cases with newly diagnosed and 59.5% cases with relapsed and refractory MM 
including complete and strong complete remission (CR/sCR) in 22.991» and 20.3% cases 
respectively. With a median follow-up of 4.9 years for the comparison groups, the 5- 
year overall survival (OS) was 22.8 ±  5.3% and 17.3 ±  4.4% (p =• 0.295). The median 
OS was 40.0 and 3 1.8 months respectively.
Conclusions: In multivariate analysis only ECOG scores >  2 were demonstrated an in­
dependent negative prognostic value both for the event-free survival (Hazard ratio 
1.69; p =  0.006) and OS (Hazard ratio 1.76; p =  0.003). Overall, the bortezomib-based 
treatment in myeloma patients with concomitant cardiac pathology accompanied by 
no significant increase in the incidence of cardiovascular adverse events.
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Background: Progress in the treatment o f acute myeloid leukemia (AML) in older pa­
tients (pts) is still limited. In the randomized part of the AMLSG 06-04 trial, valproic 
acid (VPA) was evaluated in combination with intensive therapy pita all-trans retinoic
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